Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma-Reference-Cited by-同舟云学术

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma

Published:2012-09-12 Issue:4 Volume:119 Page:799-805
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Patel Sapna P.,Lazar Alexander J.,Papadopoulos Nicholas E.,Liu Ping,Infante Jeffrey R.,Glass Michelle R.,Vaughn Carol S.,LoRusso Patricia M.,Cohen Roger B.,Davies Michael A.,Kim Kevin B.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27790/fullpdf

Reference29 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin.,2011

2. Dacarbazine-based chemotherapy for metastatic melanoma: 30-year experience overview;Serrone;J Exp Clin Cancer Res.,2000

3. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2;Rosenberg;JAMA.,1994

4. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med.,2010

5. Inhibition of mutated, activated BRAF in metastatic melanoma;Flaherty;N Engl J Med.,2010

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MEK inhibitors in oncology: a patent review and update (2016 - present);Expert Opinion on Therapeutic Patents;2024-09-14

2. MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives;RSC Medicinal Chemistry;2023

3. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment;Clinical and Experimental Medicine;2022-02-16

4. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications;Bioorganic & Medicinal Chemistry;2021-09

5. Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib;Clinical Pharmacokinetics;2020-12-23